Abstract
Filibuvir is a non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA-directed RNA polymerase (NS5B). Specifically, filibuvir works by noncovalently binding to the "thumb 2" pocket of NS5B. Phase I monotherapy studies demonstrated that filibuvir is safe, well tolerated and resulted in a rapid reduction in HCV RNA. Results from a 4-week phase IIa study of three doses of filibuvir given in combination with pegylated interferon (peg-IFN) and ribavirin, followed by 44 weeks of peg-IFN and ribavirin, showed an increased rapid virological response rate (RVR; undetectable HCV RNA after 4 weeks) compared to peg-IFN and ribavirin alone. A trial evaluating 24 weeks of filibuvir in combination with peg-IFN and ribavirin has recently completed enrollment and data from this trial will be forthcoming.
Original language | English (US) |
---|---|
Pages (from-to) | 767-775 |
Number of pages | 9 |
Journal | Drugs of the Future |
Volume | 37 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2012 |
Keywords
- Filibuvir
- Hepatitis C virus
- PF-868554
- RNA-directed RNA polymerase inhibitor
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)